US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invesco Global Clean Energy ETF

13.56

+0.13000.97%

Post-market: 13.560.00000.00%19:19 EDT

Volume:21.54K

Turnover:291.92K

Market Cap:78.31M

PE:- -

High:13.62

Open:13.49

Low:13.49

Close:13.43

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Press Release: ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PBD"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBD\",,,,,undefined,":{"symbol":"PBD","market":"US","secType":"STK","nameCN":"Invesco Global Clean Energy ETF","latestPrice":13.56,"timestamp":1752868800000,"preClose":13.43,"halted":0,"volume":21540,"hourTrading":{"tag":"盘后","latestPrice":13.56,"preClose":13.56,"latestTime":"19:19 EDT","volume":7,"amount":95.18,"timestamp":1752880742608},"delay":0,"floatShares":5775000,"shares":5775000,"eps":0,"marketStatus":"Market Closed","change":0.13,"latestTime":"07-18 16:00:00 EDT","open":13.49,"high":13.62,"low":13.49,"amount":291923.61789,"amplitude":0.00968,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":13.43,"sharesOutstanding":5775000,"nav":13.44537,"aum":78637160.54,"dividendRate":0.025811,"bidAskSpread":0.002427,"postHourTrading":{"tag":"盘后","latestPrice":13.56,"preClose":13.56,"latestTime":"19:19 EDT","volume":7,"amount":95.18,"timestamp":1752880742608},"volumeRatio":1.2353219175080035,"impliedVol":0.3677,"impliedVolPercentile":0.784},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBD\",,,,,undefined,":{"symbol":"PBD","floatShares":5775000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.2353219175080035,"shares":5775000,"dividePrice":0.35,"high":13.62,"amplitude":0.00968,"preClose":13.43,"low":13.49,"week52Low":9.02,"pbRate":"--","week52High":14.17,"institutionHeld":0,"latestPrice":13.56,"eps":0,"divideRate":0.025811,"volume":21540,"delay":0,"ttmEps":0,"open":13.49,"prevYearClose":11.57,"prevWeekClose":13.2,"prevMonthClose":12.6011,"prevQuarterClose":12.6011,"fiveDayClose":13.2,"twentyDayClose":12.16,"sixtyDayClose":10.3909},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PBD\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBD\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542513417","title":"Press Release: ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2542513417","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542513417?lang=en_us&edition=fundamental","pubTime":"2025-06-12 18:45","pubTimestamp":1749725100,"startTime":"0","endTime":"0","summary":"LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity  financing. In the PIPE, ADC Therapeutics is selling 13.0 million common shares at $3.53 per share and pre-funded warrants to purchase 15.7 million common shares at $3.43, per pre-funded warrant, which is the price per common share in the PIPE minus the exercise price of CHF 0.08 per pre-funded warrant.Gross proceeds from the PIPE financing are anticipated to be approximately $100.0 million before deducting placement agent fees and offering expenses. The PIPE is expected to close on June 16, 2025, subject to customary closing conditions. ADC Therapeutics intends to use the net proceeds from the PIPE to fund multiple catalysts pr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4232","BK4505","PBD","BK4195","BK4007","BK4231","BK4539","BK4080","PFS","BK4081","R","BK4139","ADCT","LENZ","BK4022","EMA","BK4211"],"gpt_icon":0},{"id":"2535025235","title":"Press Release: ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535025235","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535025235?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:00","pubTimestamp":1747224000,"startTime":"0","endTime":"0","summary":"LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress  and the 18 International Conference on Malignant Lymphoma ; ZYNLONTA plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability. Cash runway expected to fund multiple catalysts into the second half of 2026. LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today reported financial results for the first quarter ended March 31, 2025, and provided recent operational updates.\"We are encouraged by the promising LOTIS-7 abstract data, which we believe demonstrate the potential for ZYNLONTA plus glofitamab to be a best-in-class combination in a dynamic market,\" said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. \"Coupled with the progress of our LOTIS-5 confirmatory trial, we are confident in our path forward and the potential of ZYNLON","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LENZ","BK4539","BK4161","CR","BK4080","ADCT","BK4195","ADC","PFS","R","BK4139","ORR","BK4007","BK4211","BK4232","BK4022","PBD","BK4231"],"gpt_icon":0},{"id":"2524220685","title":"ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524220685","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524220685?lang=en_us&edition=fundamental","pubTime":"2025-04-04 14:00","pubTimestamp":1743746400,"startTime":"0","endTime":"0","summary":"Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year. Approval brings Daiichi Sankyo and AstraZeneca’s ENHERTU earlier in the treatment of HR positive, HER2 low breast cancer and broadens the eligible patient population to those with HER2 ultralow disease. HR positive, HER2 negative is the most common breast cancer subtype, accounting for approximately 70% of all breast cancers.1 Despite being classified as HER2 negative, many of these tumors still have some level of HER2 expression. Currently, regardless of HER2 expression, endocrine-based therapies are widely used in the early lines of treatment for HR positive metastatic breast cancer. Following endocrine-based therapy, some patients discontinue treatment, and others are treated with conventional chemotherapy which is associated with poor response rates and outcomes.2,3,4,5. In the DESTINY-Breast06 trial, ENHERT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-approved-eu-first-her2-060000976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DSKYF","ADC","BK4225","BK4195","BK4007","BK4231","ORR","BK4080","PFS","BK4203","BK4156","DSNKY","PBD","BK4211","HR"],"gpt_icon":0},{"id":"2523958946","title":"DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523958946","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523958946?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"TOKYO & BASKING RIDGE, N.J., March 31, 2025----The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU  in combination with a fluoropyrimidine chemotherapy  and Merck’s  anti-PD-1 therapy KEYTRUDA  versus trastuzumab in combination with platinum-based chemotherapy  and pembrolizumab in previously untreated patients with unresectable, locally advanced or metastatic HER2 positive  gastric or gastroesophageal junction  cancer with PD-L1 CPS ≥1. An exploratory cohort of patients with PD-L1 CPS <1 will be randomized to either ENHERTU plus fluoropyrimidine or trastuzumab plus platinum-based chemotherapy.Gastric cancer is associated with a poor prognosis, particularly in advanced stages of the disease where the five-year survival rate is 5% to 10%.1 Current recommended first-line treatment for HER2 positive advanced gastric cancer with PD-L1 CPS ≥1 is trastuzumab in combination with platinum-based chemotherapy  and pembrolizumab.2,3 New treatment strategies ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/destiny-gastric05-phase-3-trial-120000580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFS","BK4080","ADC","BK4157","HR","AEIS","IE00B19Z4B17.USD","BK4225","BK4195","IE00B66KJ199.SGD","DSNKY","BK4007","PBD","IE00B7SZL793.SGD","DSKYF","BK4211","BK4203","BK4231","IE0031619046.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBD\",params:#limit:5,,,undefined,":[{"date":"2025-06-23","symbol":"PBD","amount":0.13639,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Global Clean Energy ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-24","symbol":"PBD","amount":0.09252,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"Invesco Global Clean Energy ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PBD","amount":0.04487,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Invesco Global Clean Energy ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-27"},{"date":"2024-09-23","symbol":"PBD","amount":0.07114,"announcedDate":"2024-09-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-23","defaultRemindTime":1727098200000,"name":"Invesco Global Clean Energy ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-27","payableDate":"2024-09-23","currency":"USD","dateTimestamp":1727064000000,"payDate":"2024-09-27"},{"date":"2024-06-24","symbol":"PBD","amount":0.08667,"announcedDate":"2024-06-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Global Clean Energy ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBD\",market:\"US\",,,undefined,":[{"executeDate":"2015-09-18","recordDate":"2015-09-22","paymentDate":"2015-09-30","value":0.0237,"currency":"USD"},{"executeDate":"2015-12-18","recordDate":"2015-12-22","paymentDate":"2015-12-31","value":0.07386,"currency":"USD"},{"executeDate":"2016-06-17","recordDate":"2016-06-21","paymentDate":"2016-06-30","value":0.0645,"currency":"USD"},{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-30","value":0.06879,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.0793,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBD\",market:\"US\",delay:false,,,undefined,":{}}}